AEGiS-Reuters: New AIDS Coalition Aims to Boost Access to Drugs

Reuters, Ltd.Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu


DonateNow


New AIDS Coalition Aims to Boost Access to Drugs

Reuters NewMedia - Thursday December 12, 2002


GENEVA (Reuters) - U.N. agencies joined governments and health groups on Thursday in launching a new drive to get life-prolonging drugs to millions of AIDS sufferers in poor countries, where currently only one-in-20 has treatment.

The International HIV Treatment Access Coalition (ITAC), bringing together a host of organizations ranging from the World Health Organization (WHO) to Brazil's Health Ministry, aims to boost that ratio sharply.

Only some 300,000 AIDS sufferers, or five percent of the total in low- to middle-income countries, have access to HIV-related medicines, compared with almost 100 percent in rich countries.

The United Nations has set a target of boosting the number in treatment in poorer states to three million by 2005. Of the 42 million people infected with HIV, 95 percent live in developing countries. "This should have happened yesterday but at least it is starting now. We have already lost too many lives," Fezeka Ntsukela Kuzwayo, a South African community worker living with the AIDS-causing HIV virus, told a news conference.

Organizers said the coalition would share information on "best practices" in the purchasing and use of medicines, evaluate health programs and keep up the international pressure for cheaper drugs.

"If we continue as we are today, we will never reach the U.N. target," said professor Joep Lange, President of the International AIDS Society and coordinator of the new coalition.

"We need to map out what needs to be done but nobody can do that alone," he said.


021212
RE021221


Copyright © 2002 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .